Walker SR - Search Results

1

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K. Marotta LL, et al. Among authors: walker sr. J Clin Invest. 2011 Jul;121(7):2723-35. doi: 10.1172/JCI44745. J Clin Invest. 2011. PMID: 21633165 Free PMC article.

2

Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification.

Nelson EA, Walker SR, Alvarez JV, Frank DA. Nelson EA, et al. Among authors: walker sr. J Biol Chem. 2004 Dec 24;279(52):54724-30. doi: 10.1074/jbc.M408464200. Epub 2004 Oct 20. J Biol Chem. 2004. PMID: 15498775 Free article.

3

STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.

Walker SR, Nelson EA, Frank DA. Walker SR, et al. Oncogene. 2007 Jan 11;26(2):224-33. doi: 10.1038/sj.onc.1209775. Epub 2006 Jul 3. Oncogene. 2007. PMID: 16819511

4

Identification of human STAT5-dependent gene regulatory elements based on interspecies homology.

Nelson EA, Walker SR, Li W, Liu XS, Frank DA. Nelson EA, et al. Among authors: walker sr. J Biol Chem. 2006 Sep 8;281(36):26216-24. doi: 10.1074/jbc.M605001200. Epub 2006 Jul 13. J Biol Chem. 2006. PMID: 16840779 Free PMC article.

5

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA. Nelson EA, et al. Among authors: walker sr. Blood. 2008 Dec 15;112(13):5095-102. doi: 10.1182/blood-2007-12-129718. Epub 2008 Sep 29. Blood. 2008. PMID: 18824601 Free PMC article.

6

Reciprocal effects of STAT5 and STAT3 in breast cancer.

Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA. Walker SR, et al. Mol Cancer Res. 2009 Jun;7(6):966-76. doi: 10.1158/1541-7786.MCR-08-0238. Epub 2009 Jun 2. Mol Cancer Res. 2009. PMID: 19491198

7

Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling.

Walker SR, Chaudhury M, Nelson EA, Frank DA. Walker SR, et al. Mol Pharmacol. 2010 Nov;78(5):903-8. doi: 10.1124/mol.110.066316. Epub 2010 Aug 6. Mol Pharmacol. 2010. PMID: 20693278

8

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.

Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA. Nelson EA, et al. Among authors: walker sr. Blood. 2011 Mar 24;117(12):3421-9. doi: 10.1182/blood-2009-11-255232. Epub 2011 Jan 13. Blood. 2011. PMID: 21233313 Free PMC article.

9

STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.

Walker SR, Chaudhury M, Frank DA. Walker SR, et al. Mol Cell Pharmacol. 2011 Jan 1;3(1):13-19. Mol Cell Pharmacol. 2011. PMID: 21949561 Free PMC article.

10

Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.

Bar-Natan M, Nelson EA, Walker SR, Kuang Y, Distel RJ, Frank DA. Bar-Natan M, et al. Among authors: walker sr. Leukemia. 2012 Jun;26(6):1407-10. doi: 10.1038/leu.2011.338. Epub 2011 Dec 2. Leukemia. 2012. PMID: 22134716 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters